Oncologist : Impact Factor & More
eISSN: 1549-490XpISSN: 1083-7159
Open AccessShare this on:
Key Metrics
CiteScore 
8.5
Impact Factor
5 - 10
SNIP
1.61
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Oncologist Journal Specifications
| Overview | |
| Publisher | OXFORD UNIV PRESS |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 3494 |
| Publication Time | 19 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Society for Translational Oncology |
| Frequency | Monthly |
| Publication Start Year | 1996 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Oncologist ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Oncologist
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and Equity.
- 13 Mar 2026
- The oncologist
Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer.
- 13 Mar 2026
- The oncologist
Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study.
- 13 Mar 2026
- The oncologist
PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis.
- 12 Mar 2026
- The oncologist
Limited Discriminatory Performance of the iMCD-IPI in a Western Cohort.
- 12 Mar 2026
- The oncologist
Infertility, Anxiety, and Depression among Adolescents and Young Adults with Cancer: The Mexico Cancer Survivorship Registry.
- 9 Mar 2026
- The oncologist
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and Equity.
- 13 Mar 2026
- The oncologist
Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer.
- 13 Mar 2026
- The oncologist
Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study.
- 13 Mar 2026
- The oncologist
PD-1 inhibitor treatment outcomes for cutaneous squamous cell carcinoma in patients over 85: a comparative analysis.
- 12 Mar 2026
- The oncologist
Limited Discriminatory Performance of the iMCD-IPI in a Western Cohort.
- 12 Mar 2026
- The oncologist
Infertility, Anxiety, and Depression among Adolescents and Young Adults with Cancer: The Mexico Cancer Survivorship Registry.
- 9 Mar 2026
- The oncologist
FAQs on Oncologist
How long has Oncologist been actively publishing? 
What is the publishing frequency of Oncologist?
How many articles did Oncologist publish last year?
What is the eISSN & pISSN for Oncologist?
What is Citescore for Oncologist?
What is SNIP score for Oncologist?
Who is the publisher of Oncologist?
